

a cover substrate film comprising a second polymer, the cover substrate film covering the first deposit and joined to said first base substrate film by a first bond that surrounds said deposit, said active ingredient being present in an amount that does not vary from a target amount by more than 5 weight per cent.

## Add the following claims:

38 (new). A pharmaceutical unit dosage form, comprising:

a polymeric first base substrate film;

a first deposit, including a first active ingredient, deposited on a surface of said first base substrate film;

a polymeric first cover substrate film, covering the first deposit and joined to said first base substrate film by a first bond that surrounds said first deposit, said first active ingredient being present in an amount that does not vary from a target amount by more than 5 weight percent; and

a second deposit, including a second active ingredient, deposited on a surface of said first cover substrate film, said second active ingredient being present in an amount that does not vary from a target amount by more than 5 weight percent, wherein

said second active ingredient is different from said first active ingredient, and said second deposit overlies said first deposit.

39 (new). The pharmaceutical unit dosage form of claim 38, further comprising a polymeric second cover substrate film, covering the second deposit and joined to said first base substrate film by a second bond that surrounds said first deposit.

40 (new): A pharmaceutical unit dosage form, comprising:

a polymeric first base substrate film;

a first deposit, including a first active ingredient, deposited on a surface of said first base substrate film;

a polymeric first cover substrate film, covering the first deposit and joined to said first base substrate film by a first bond that surrounds said first deposit, said first active ingredient being present in an amount that does not vary from a target amount by more than 5 weight percent;

a polymeric second base substrate film, overlying said first cover substrate film and said first deposit; and

a second deposit, including a second active ingredient, deposited on a surface of said second base substrate film, said second active ingredient being present in an amount that does not vary from a target amount by more than 5 weight percent, wherein

said second active ingredient is different from said first active ingredient, and said second deposit overlies said first deposit.

41 (new). The pharmaceutical unit dosage form of claim 40, further comprising a polymeric second cover substrate film, covering the second deposit and joined to said first base substrate film by a second bond that surrounds said first deposit.

## **REMARKS**

Claims 1-10, 17-19, 21-35 and 38-41 are active. Claims 38-41 are new. The rejection of claims 1-10, 17-19 and 21-35 under 35 USC 102 as being anticipated by Mlodozeniec is withdrawn. Claims 1-10, 17-19 and 21-35 are rejected under 35 USC 103 as being unpatentable over Mlodozeniec.